Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever

Israel Medical Association Journal

Volumn 14, Issue 4, 2012, Pages 221-223

  Ben Zvi, Ilan ^a   Danilesko, Iveta ^a   Yahalom, Gilad ^a   Kukuy, Olesya ^a   Rahamimov, Ruth ^b,c   Livneh, Avi ^a,c   Kivity, Shaye ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Amyloidosis; Colchicine; Familial mediterranean fever (FMF); Genetics; Kidney transplantation

Indexed keywords

ALANINE; COLCHICINE; GLUTAMIC ACID; GLUTAMINE; METHIONINE; VALINE;

ADULT; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; HUMAN; IMMUNOSUPPRESSIVE TREEATMENT; KIDNEY AMYLOIDOSIS; KIDNEY TRANSPLANTATION; MALE; MEFV GENE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RESTRICTION MAPPING; RETROSPECTIVE STUDY;

ADULT; AMYLOIDOSIS; CASE-CONTROL STUDIES; COLCHICINE; CROSS-SECTIONAL STUDIES; CYTOSKELETAL PROTEINS; ETHNIC GROUPS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84860313531     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Pras M, Bronshpigel N, Zemer D, Gafni J. Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups. Johns Hopkins Med J 1982; 150 (1): 22-6.
2. El-Shanti HI. Familial Mediterranean fever and renal disease. Saudi J Kidney Dis Transpl 2003; 14 (3): 378-85.
3. Livneh A. Amyloidosis of familial Mediterranean fever (FMF) - insights to FMF phenotype II. Harefuah 2006; 145 (10): 743-5, 82 (Hebrew).
4. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003; 48 (4): 1149-55.
5. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974; 291 (18): 932-4.
6. Sevoyan MK, Sarkisian TF, Beglaryan AA, Shahsuvaryan GR, Armenian HK. Prevention of amyloidosis in familial Mediterranean fever with colchicine: a case-control study in Armenia. Med Princ Pract 2009; 18 (6): 441-6.
7. Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992; 60 (4): 418-22.
8. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40 (10): 1879-85.
9. Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 2005; 35 (1): 57-64.
10. Kogan A, Shinar Y, Lidar M, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001; 102 (3): 272-6.
11. Livneh A, Langevitz P, Shinar Y, et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 1999; 6 (1): 1-6.
12. Zaks N, Shinar Y, Padeh S, et al. Analysis of the three most common MEFV